Bliss GVS Pharma Limited (BLISSGVS.NS)
INR 169.0
(0.87%)
INR 169.0
(0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.47 Billion INR | 11.48% |
| 2022 | 1.35 Billion INR | -18.12% |
| 2021 | 762.36 Million INR | 29.71% |
| 2020 | 1.26 Billion INR | -21.45% |
| 2019 | 1.49 Billion INR | -21.35% |
| 2018 | 1.95 Billion INR | 61.05% |
| 2017 | 816.66 Million INR | -39.72% |
| 2016 | 1.11 Billion INR | 13.12% |
| 2015 | 1.78 Billion INR | 51.6% |
| 2014 | 1.23 Billion INR | 67.22% |
| 2013 | 739.72 Million INR | -33.18% |
| 2012 | 1.1 Billion INR | 27.1% |
| 2011 | 870.95 Million INR | 43.73% |
| 2010 | -284.13 Million INR | 13.91% |
| 2009 | 536.91 Million INR | 15.39% |
| 2008 | 461.06 Million INR | 16.6% |
| 2007 | 395.41 Million INR | 318.57% |
| 2006 | 94.47 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 343.3 Million INR | 1030.62% |
| 2024 Q2 | 465.14 Million INR | 20.96% |
| 2023 Q3 | 491.16 Million INR | -26.66% |
| 2023 Q1 | 293.26 Million INR | 218.13% |
| 2023 FY | - INR | 11.48% |
| 2023 Q4 | 283.47 Million INR | -42.28% |
| 2023 Q2 | 669.7 Million INR | 128.36% |
| 2022 Q2 | 266.96 Million INR | -41.79% |
| 2022 Q4 | 92.18 Million INR | -82.72% |
| 2022 FY | - INR | -18.12% |
| 2022 Q1 | 458.62 Million INR | -3.52% |
| 2022 Q3 | 533.32 Million INR | 99.78% |
| 2021 Q4 | 475.37 Million INR | 18.25% |
| 2021 Q1 | 424.18 Million INR | 80.04% |
| 2021 FY | - INR | 29.71% |
| 2021 Q2 | 348.58 Million INR | -17.82% |
| 2021 Q3 | 402.01 Million INR | 15.33% |
| 2020 Q2 | 347.44 Million INR | 31.02% |
| 2020 Q1 | 265.18 Million INR | -22.16% |
| 2020 FY | - INR | -21.45% |
| 2020 Q4 | 235.6 Million INR | -44.42% |
| 2020 Q3 | 423.94 Million INR | 22.02% |
| 2019 Q4 | 340.69 Million INR | -11.42% |
| 2019 Q1 | 510.73 Million INR | 12.53% |
| 2019 Q2 | 383.62 Million INR | -24.89% |
| 2019 Q3 | 384.62 Million INR | 0.26% |
| 2019 FY | - INR | -21.35% |
| 2018 FY | - INR | 61.05% |
| 2018 Q3 | 396.37 Million INR | -40.31% |
| 2018 Q4 | 453.86 Million INR | 14.5% |
| 2018 Q2 | 664.02 Million INR | 21.83% |
| 2018 Q1 | 545.03 Million INR | 26.53% |
| 2017 Q4 | 430.76 Million INR | -14.52% |
| 2017 FY | - INR | -39.72% |
| 2017 Q2 | 626.18 Million INR | -7.35% |
| 2017 Q1 | 675.85 Million INR | -7.86% |
| 2017 Q3 | 503.95 Million INR | -19.52% |
| 2016 Q1 | 480.82 Million INR | -7.8% |
| 2016 FY | - INR | 13.12% |
| 2016 Q4 | 733.52 Million INR | 38.55% |
| 2016 Q3 | 529.41 Million INR | 18.06% |
| 2016 Q2 | 448.44 Million INR | -6.73% |
| 2015 Q2 | 512.99 Million INR | 23.88% |
| 2015 FY | - INR | 51.6% |
| 2015 Q4 | 521.47 Million INR | 48.1% |
| 2015 Q3 | 352.1 Million INR | -31.36% |
| 2015 Q1 | 414.12 Million INR | 0.0% |
| 2014 FY | - INR | 67.22% |
| 2013 FY | - INR | -33.18% |
| 2012 Q4 | 203.64 Million INR | -25.85% |
| 2012 FY | - INR | 27.1% |
| 2012 Q1 | 258.08 Million INR | 0.0% |
| 2012 Q2 | 377.38 Million INR | 46.23% |
| 2012 Q3 | 274.62 Million INR | -27.23% |
| 2011 FY | - INR | 43.73% |
| 2010 FY | - INR | 13.91% |
| 2009 FY | - INR | 15.39% |
| 2008 FY | - INR | 16.6% |
| 2007 FY | - INR | 318.57% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | -67.425% |
| Ind-Swift Limited | 1.06 Billion INR | -38.867% |
| Bajaj HealthCare Limited | 406.23 Million INR | -264.08% |
| Sakar Healthcare Limited | 393.26 Million INR | -276.087% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.606% |
| Innova Captab Limited | 1.66 Billion INR | 11.346% |
| Divi's Laboratories Limited | 25.43 Billion INR | 94.184% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 37.244% |
| Morepen Laboratories Limited | 1.72 Billion INR | 14.307% |
| Mankind Pharma Limited | 28.09 Billion INR | 94.736% |
| Sequent Scientific Limited | 549.8 Million INR | -169.012% |
| Wanbury Limited | 985.49 Million INR | -50.081% |
| Laurus Labs Limited | 8 Billion INR | 81.526% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 3.683% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 78.449% |
| Alembic Limited | 1.11 Billion INR | -32.489% |
| Hikal Limited | 2.69 Billion INR | 45.063% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 84.62% |
| Neuland Laboratories Limited | 4.74 Billion INR | 68.851% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 84.156% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 86.962% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 43.258% |
| Themis Medicare Limited | 562.6 Million INR | -162.889% |
| RPG Life Sciences Limited | 1.28 Billion INR | -15.414% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.369% |
| Lupin Limited | 36.96 Billion INR | 95.999% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -116.995% |
| Wockhardt Limited | 1.08 Billion INR | -36.947% |
| Vaishali Pharma Limited | 31.71 Million INR | -4564.091% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 62.168% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -357.253% |
| Jubilant Pharmova Limited | 8 Billion INR | 81.526% |
| FDC Limited | 3.38 Billion INR | 56.311% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.325% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -414.579% |
| Eris Lifesciences Limited | 6.98 Billion INR | 78.83% |
| Venus Remedies Limited | 711.8 Million INR | -107.787% |
| ZIM Laboratories Limited | 462.09 Million INR | -220.069% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -548.203% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 76.082% |
| Shilpa Medicare Limited | 2.58 Billion INR | 42.85% |
| Albert David Limited | 1.04 Billion INR | -41.477% |
| Ajanta Pharma Limited | 12.56 Billion INR | 88.229% |
| Hester Biosciences Limited | 539.47 Million INR | -174.164% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 68.378% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 152.413% |
| Gufic Biosciences Limited | 1.48 Billion INR | 0.098% |
| Windlas Biotech Limited | 781.72 Million INR | -89.202% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 51.892% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -3174.726% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -745.421% |
| Granules India Limited | 8.6 Billion INR | 82.81% |
| Aarti Drugs Limited | 3.24 Billion INR | 54.472% |
| Bal Pharma Limited | 345.59 Million INR | -327.97% |
| Alkem Laboratories Limited | 24.19 Billion INR | 93.887% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.931% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -10.102% |
| Medicamen Biotech Limited | 245.66 Million INR | -502.064% |
| Unichem Laboratories Limited | 742.35 Million INR | -99.235% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -1190.794% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -11280.656% |
| Valiant Laboratories Limited | 12.73 Million INR | -11510.252% |
| Orchid Pharma Limited | 1.41 Billion INR | -4.217% |
| Medico Remedies Limited | 129.09 Million INR | -1045.7% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 78.445% |
| Ipca Laboratories Limited | 13.29 Billion INR | 88.879% |
| Brooks Laboratories Limited | 41.72 Million INR | -3444.455% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -243.74% |
| Piramal Enterprises Limited | -3.86 Billion INR | 138.306% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.775% |
| NATCO Pharma Limited | 18.79 Billion INR | 92.131% |
| Suven Life Sciences Limited | -992.78 Million INR | 248.979% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1887.844% |
| Strides Pharma Science Limited | 3.76 Billion INR | 60.713% |
| Indoco Remedies Limited | 2.64 Billion INR | 44.125% |
| Alpa Laboratories Limited | 229.96 Million INR | -543.166% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2372.634% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 139.637% |